MX285869B - Benzoxazines and related nitrogen-containing heterobicyclic compounds useful as mineralocorticoid receptor modulating agents - Google Patents

Benzoxazines and related nitrogen-containing heterobicyclic compounds useful as mineralocorticoid receptor modulating agents

Info

Publication number
MX285869B
MX285869B MX2008010022A MX2008010022A MX285869B MX 285869 B MX285869 B MX 285869B MX 2008010022 A MX2008010022 A MX 2008010022A MX 2008010022 A MX2008010022 A MX 2008010022A MX 285869 B MX285869 B MX 285869B
Authority
MX
Mexico
Prior art keywords
benzoxazines
compounds useful
modulating agents
mineralocorticoid receptor
receptor modulating
Prior art date
Application number
MX2008010022A
Other languages
English (en)
Inventor
T Iijima
Y Yamamoto
H Akatsuka
T Kawaguchi
Original Assignee
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Tanabe Pharma Corp filed Critical Mitsubishi Tanabe Pharma Corp
Publication of MX285869B publication Critical patent/MX285869B/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D265/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/281,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/341,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/361,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/5381,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D279/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/101,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/141,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
    • C07D279/161,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
MX2008010022A 2006-02-02 2008-08-01 Benzoxazines and related nitrogen-containing heterobicyclic compounds useful as mineralocorticoid receptor modulating agents MX285869B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006025403 2006-02-02
JP2006275917 2006-10-10

Publications (1)

Publication Number Publication Date
MX285869B true MX285869B (en) 2011-04-19

Family

ID=38110055

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2008010022A MX285869B (en) 2006-02-02 2008-08-01 Benzoxazines and related nitrogen-containing heterobicyclic compounds useful as mineralocorticoid receptor modulating agents

Country Status (16)

Country Link
US (2) US7998956B2 (es)
EP (1) EP1984345B9 (es)
KR (1) KR101046548B1 (es)
AR (1) AR059280A1 (es)
AT (1) ATE522511T1 (es)
AU (1) AU2007210424C1 (es)
BR (1) BRPI0707491B8 (es)
CA (1) CA2636985C (es)
DK (1) DK1984345T3 (es)
MX (1) MX285869B (es)
PH (1) PH12008501738B1 (es)
PL (1) PL1984345T3 (es)
PT (1) PT1984345E (es)
RU (1) RU2398769C2 (es)
TW (1) TWI385161B (es)
WO (1) WO2007089034A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8940900B2 (en) * 2007-02-28 2015-01-27 Advinus Therapeutics Private Limited 2,2,2-tri-substituted acetamide derivatives as glucokinase activators, their process and pharmaceutical application
US8258131B2 (en) 2007-08-01 2012-09-04 Mitsubishi Tanabe Pharma Corporation Fused bicyclic compound
CA2718709C (en) * 2008-03-31 2016-08-09 C & C Research Laboratories Heterocyclic derivatives
JP2011516494A (ja) * 2008-04-07 2011-05-26 ギリアード サイエンシーズ, インコーポレイテッド ステアロイル−CoAデサチュラーゼの阻害剤として使用するための2H−ベンゾ[b][1,4]オキサジン−3(4H)−オン誘導体
CR20200286A (es) 2011-12-22 2020-09-23 Novartis Ag DERIVADOS DE DIHIDRO-BENZO-OXAZINA Y DIHIDRO-PIRIDO-OXAZINA (Divisional 2014-0294)
US9051311B2 (en) 2012-03-09 2015-06-09 Amgen Inc. Sulfamide sodium channel inhibitors
ES2698959T3 (es) 2012-08-08 2019-02-06 Mitsubishi Tanabe Pharma Corp Método para producir un compuesto de 1,4-benzoxazina
US9212182B2 (en) 2013-06-12 2015-12-15 Amgen Inc. Bicyclic sulfonamide compounds as sodium channel inhibitors
RU2727169C2 (ru) 2013-11-18 2020-07-21 Форма Терапеутикс Инк. Композиции тетрагидрохинолинов в качестве ингибиторов бромодомена вет
EP3071205B1 (en) 2013-11-18 2020-02-05 Forma Therapeutics, Inc. Benzopiperazine compositions as bet bromodomain inhibitors
CN103694137A (zh) * 2013-12-06 2014-04-02 常州工程职业技术学院 一种2-氟-4-硝基苯甲腈的清洁生产方法
EA029518B1 (ru) 2014-06-30 2018-04-30 Астразенека Аб Бензоксазиноновые амиды в качестве модуляторов минералокортикоидного рецептора
US20180280414A1 (en) 2015-10-13 2018-10-04 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of choroidal neovascularisation
ES2973248T3 (es) 2016-07-26 2024-06-19 Inst Nat Sante Rech Med Antagonista del receptor mineralocorticoide para el tratamiento de la osteoartritis
TWI603962B (zh) 2016-09-10 2017-11-01 國立清華大學 含硫噁嗪化合物及其合成方法
MX2019003470A (es) 2016-09-27 2019-08-29 Mitsubishi Tanabe Pharma Corp Composicion farmaceutica y metodo para el tratamiento de la enfermedad del higado graso no alcoholico.
EP3525779B1 (de) 2016-10-11 2024-06-05 Bayer Pharma Aktiengesellschaft Kombination enthaltend den sgc stimulator vericuguat und den mineralcorticoid-rezeptor-antagonist finerenone
CN109890379A (zh) 2016-10-11 2019-06-14 拜耳制药股份公司 包含sGC活化剂和盐皮质激素受体拮抗剂的组合产品
WO2018149754A1 (en) 2017-02-16 2018-08-23 Basf Se Pyridine compounds
WO2018153898A1 (de) 2017-02-22 2018-08-30 Bayer Pharma Aktiengesellschaft Selektive partielle adenosin a1 rezeptor-agonisten in kombination mit mineralocorticoid-rezeptor-antagonisten
DE102017008472A1 (de) 2017-09-08 2018-05-03 Bayer Pharma Aktiengesellschaft Kombination enthaltend PDE5 Inhibitoren und Mineralocorticoid-Rezeptor-Antagonisten
AR117988A1 (es) 2019-02-05 2021-09-08 Mitsubishi Tanabe Pharma Corp Medicamento para profilaxis o tratamiento para la fibrosis pulmonar
WO2021107029A1 (ja) 2019-11-26 2021-06-03 田辺三菱製薬株式会社 ヒトの非アルコール性脂肪肝炎の予防薬または治療薬
JP2023518168A (ja) 2020-03-11 2023-04-28 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 対象が中心性漿液性脈絡網膜症を有するか、または有する危険性があるかどうかを決定する方法。
WO2023031277A1 (en) 2021-08-31 2023-03-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of ocular rosacea

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5420126A (en) 1989-11-08 1995-05-30 Yamanouchi Pharmaceutical Co., Ltd. 3,4-dihydro-2H-1,4-benzoxazine derivatives and pharmaceutical compositions containing the same
TW224941B (es) 1989-11-08 1994-06-11 Yamanouchi Pharma Co Ltd
CN1029479C (zh) 1989-11-08 1995-08-09 山之内制药株式会社 新型苯并噁嗪衍生物的制备方法
US5696117A (en) 1995-11-07 1997-12-09 Ortho Pharmaceutical Corporation Benzoxazine antimicrobial agents
DE19727117A1 (de) 1997-06-26 1999-01-07 Boehringer Ingelheim Pharma Phenylalkylderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US6498154B1 (en) * 1999-05-04 2002-12-24 Wyeth Cyclic regimens using quinazolinone and benzoxazine derivatives
US6509334B1 (en) * 1999-05-04 2003-01-21 American Home Products Corporation Cyclocarbamate derivatives as progesterone receptor modulators
US6358948B1 (en) * 1999-05-04 2002-03-19 American Home Products Corporation Quinazolinone and benzoxazine derivatives as progesterone receptor modulators
EP1255743A1 (en) * 2000-02-01 2002-11-13 Millenium Pharmaceuticals, Inc. 3,4-DIHYDRO-2H-BENZO[1,4]OXAZINE INHIBITORS OF FACTOR Xa
UA73119C2 (en) * 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
CN1742007A (zh) * 2003-01-22 2006-03-01 伊莱利利公司 甾族激素核受体的吲哚衍生物调控剂
SI1697350T1 (sl) 2003-12-19 2008-12-31 Lilly Co Eli Modulatorji jedrnega receptorja tricikličnih steroidnih hormonov
JP2007230869A (ja) 2004-04-05 2007-09-13 Takeda Chem Ind Ltd アルドステロン受容体拮抗剤
WO2006077821A1 (ja) 2005-01-19 2006-07-27 Dainippon Sumitomo Pharma Co., Ltd. アルドステロン受容体調節剤としての芳香族スルホン化合物

Also Published As

Publication number Publication date
EP1984345B9 (en) 2012-03-21
BRPI0707491B8 (pt) 2021-05-25
DK1984345T3 (da) 2011-12-12
CA2636985C (en) 2011-08-16
BRPI0707491A2 (pt) 2011-05-03
BRPI0707491B1 (pt) 2019-12-10
TWI385161B (zh) 2013-02-11
US20090023716A1 (en) 2009-01-22
KR20080083698A (ko) 2008-09-18
AR059280A1 (es) 2008-03-19
US7998956B2 (en) 2011-08-16
WO2007089034A1 (en) 2007-08-09
RU2398769C2 (ru) 2010-09-10
PT1984345E (pt) 2011-09-08
CA2636985A1 (en) 2007-08-09
PL1984345T3 (pl) 2012-01-31
ATE522511T1 (de) 2011-09-15
TW200800926A (en) 2008-01-01
EP1984345B1 (en) 2011-08-31
AU2007210424B2 (en) 2010-07-15
PH12008501738B1 (en) 2013-11-29
KR101046548B1 (ko) 2011-07-05
EP1984345A1 (en) 2008-10-29
RU2008135468A (ru) 2010-03-10
US20110251185A1 (en) 2011-10-13
AU2007210424A1 (en) 2007-08-09
US8188073B2 (en) 2012-05-29
AU2007210424C1 (en) 2010-11-18

Similar Documents

Publication Publication Date Title
MX285869B (en) Benzoxazines and related nitrogen-containing heterobicyclic compounds useful as mineralocorticoid receptor modulating agents
IL183665A0 (en) Heterocyclic compounds as ccr2b antagonists
ZA200806392B (en) Phenyl-cycloalkyl and phenyl-heterocyclic derivatives as SIP receptor agonists
HK1167397A1 (zh) 作為抗癌症劑的 -取代的喹唑酮衍生物
PT2155818T (pt) Composições de juntas
HK1147674A1 (en) Heterocyclic compounds as crth2 receptor antagonists crth2
IL198241A0 (en) Pyrazoline compounds as mineralocorticoid receptor antagonists
EP2188271A4 (en) HETEROCYCLIC COMPOUNDS AND USES AS ANTICANCER AGENTS
IL194815A0 (en) Fused heterocyclic compounds and their use as mglur5 modulators
IL195158A0 (en) Novel heterocyclic compounds
HK1115125A1 (en) 3-ethylidenehydrazino substituted heterocyclic compounds as thrombopoietin receptor activators
EP1991200A4 (en) FLUORCHINOLONZUSAMMENSETZUNGEN
IL199971A0 (en) Heterocyclic derivatives as m3 muscarinic receptors
EP2025671A4 (en) NITROGENIC HETEROCYCLIC COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR
EP2065439A4 (en) polyolefin
EP2039695A4 (en) BICYCLIC HETEROCYLIC COMPOUND AND ITS USE
ZA200705159B (en) Heterocyclic compounds as CCR2B antagonists
EP2258676A4 (en) STABLE VINAMIDINIUM SALT AND USE THEREOF IN THE SYNTHESIS OF NITROGENIC HETEROCYCLIC CYCLES
IL189463A0 (en) Non-steroidal compounds useful as glucocorticoid receptor modulators
ZA200704979B (en) 3-ethylidenehydrazino substituted heterocyclic compounds as thrombopoietin receptor activators
GB0619308D0 (en) Heterocyclic compounds
IL173733A0 (en) Microbial compositions useful for the degradation of hydrocarbons
GB0624212D0 (en) Heterobicyclic, nitrogen-containing compounds
ZA200809385B (en) Novel heterocyclic compounds
RS56117B1 (sr) Derivati 5-supstituisanog hinazolinona kao antikancer agensi

Legal Events

Date Code Title Description
FG Grant or registration